LINCOLN, Neb., April 27 /PRNewswire-FirstCall/ -- In remarks at the
annual shareholders meeting, Pfizer Chairman and Chief Executive Officer
Hank McKinnell told shareholders that the company has "more than turned the
corner" in research and development, with more than 150 new medicines in
development and more than 80 other projects underway. He noted that with
four new products launched in 2005 and six more planned in 2006, "2005 and
2006 will be the two best launch years in Pfizer's history."
He added: "Pfizer is succeeding in finding, developing and bringing
forward the innovations that bring hope to patients, jobs for communities
and value for investors. We are building the Pfizer for the next generation
-- a company whose future lies in a new wave of medicines now beginning to
reach patients. We serve shareholders best by serving patients first, and
our aim is to return Pfizer to its hallmark strong growth in shareholder
value over the long-term."
In other business, all 13 of the company's directors stood for and were
re-elected to one-year terms. In other voting, shareholders approved both
the selection of KPMG as Pfizer's independent auditor for 2006 and
management proposal to amend Pfizer's charter to eliminate the
supermajority vote requirements and fair price provision. No shareholder
resolutions receive a majority vote.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html /
CONTACT:
Paul Fitzhenry, of Pfizer Inc,
+1-212-733-4637
|
